Insmed vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Insmed Inc (INSM)

Q3 202623 Jun – 7 Aug 2026

▲4

Insmed's Brinsupri Launch Accelerates, Peak-Sales Target Raised to $14B

Q2 loss narrows sharply, Brinsupri guidance raised Insmed's Q2 net loss shrank to $13.2 million from $321.7 million a year earlier, and product revenue nearly quadrupled to $425.5 million. Brinsupri sales hit $309.2 million, up 49% from the prior quarter, and management raised 2026 Brinsupri guidance to $1.25–$1.40 billion. The stock jumped 33% on the news.
This is the period's biggest price-moving event and shows the core business is performing far better than expected.
Peak-sales estimate raised to over $14 billion Management now sees peak sales for its three lead programs exceeding $14 billion, a 75% increase. More than $7 billion is tied to already-launched Brinsupri, but over $6 billion depends on TPIP, which is still in Phase III trials for only two of four target indications. Insmed ended June with $1.2 billion in cash, enough to reach profitability in 2027 without raising capital.
This gives investors a long-term growth target and shows the company can fund itself, but also flags the pipeline risk.
Positive 12-month TPIP data supports Phase 3 launch Insmed reported positive 12-month data for TPIP in pulmonary arterial hypertension, with sustained improvements in exercise capacity and no new safety signals. This supports launching the PALM-PAH Phase 3 trial. TPIP is a key part of the $6 billion-plus peak-sales opportunity that still needs late-stage success.
It de-risks a major pipeline asset that underpins a large chunk of the raised peak-sales estimate.
EMBARC to run 3,000-patient brensocatib study The European bronchiectasis research group EMBARC will collaborate with Insmed on a 3,000-patient study of brensocatib (Brinsupri) across six countries. The study aims to show whether early treatment can change the disease course, which could expand use and strengthen the case for the drug beyond current approvals.
It signals strong clinical interest and potential for broader use, supporting long-term demand for the main growth driver.

July 202623 Jun – 7 Aug 2026

▲4

Insmed's Brinsupri Launch Accelerates, Peak-Sales Target Raised to $14B

Q2 loss narrows sharply, Brinsupri guidance raised Insmed's Q2 net loss shrank to $13.2 million from $321.7 million a year earlier, and product revenue nearly quadrupled to $425.5 million. Brinsupri sales hit $309.2 million, up 49% from the prior quarter, and management raised 2026 Brinsupri guidance to $1.25–$1.40 billion. The stock jumped 33% on the news.
This is the period's biggest price-moving event and shows the core business is performing far better than expected.
Peak-sales estimate raised to over $14 billion Management now sees peak sales for its three lead programs exceeding $14 billion, a 75% increase. More than $7 billion is tied to already-launched Brinsupri, but over $6 billion depends on TPIP, which is still in Phase III trials for only two of four target indications. Insmed ended June with $1.2 billion in cash, enough to reach profitability in 2027 without raising capital.
This gives investors a long-term growth target and shows the company can fund itself, but also flags the pipeline risk.
Positive 12-month TPIP data supports Phase 3 launch Insmed reported positive 12-month data for TPIP in pulmonary arterial hypertension, with sustained improvements in exercise capacity and no new safety signals. This supports launching the PALM-PAH Phase 3 trial. TPIP is a key part of the $6 billion-plus peak-sales opportunity that still needs late-stage success.
It de-risks a major pipeline asset that underpins a large chunk of the raised peak-sales estimate.
EMBARC to run 3,000-patient brensocatib study The European bronchiectasis research group EMBARC will collaborate with Insmed on a 3,000-patient study of brensocatib (Brinsupri) across six countries. The study aims to show whether early treatment can change the disease course, which could expand use and strengthen the case for the drug beyond current approvals.
It signals strong clinical interest and potential for broader use, supporting long-term demand for the main growth driver.

Latest23 Jun – 7 Aug 2026

▲4

Insmed's Brinsupri Launch Accelerates, Peak-Sales Target Raised to $14B

Q2 loss narrows sharply, Brinsupri guidance raised Insmed's Q2 net loss shrank to $13.2 million from $321.7 million a year earlier, and product revenue nearly quadrupled to $425.5 million. Brinsupri sales hit $309.2 million, up 49% from the prior quarter, and management raised 2026 Brinsupri guidance to $1.25–$1.40 billion. The stock jumped 33% on the news.
This is the period's biggest price-moving event and shows the core business is performing far better than expected.
Peak-sales estimate raised to over $14 billion Management now sees peak sales for its three lead programs exceeding $14 billion, a 75% increase. More than $7 billion is tied to already-launched Brinsupri, but over $6 billion depends on TPIP, which is still in Phase III trials for only two of four target indications. Insmed ended June with $1.2 billion in cash, enough to reach profitability in 2027 without raising capital.
This gives investors a long-term growth target and shows the company can fund itself, but also flags the pipeline risk.
Positive 12-month TPIP data supports Phase 3 launch Insmed reported positive 12-month data for TPIP in pulmonary arterial hypertension, with sustained improvements in exercise capacity and no new safety signals. This supports launching the PALM-PAH Phase 3 trial. TPIP is a key part of the $6 billion-plus peak-sales opportunity that still needs late-stage success.
It de-risks a major pipeline asset that underpins a large chunk of the raised peak-sales estimate.
EMBARC to run 3,000-patient brensocatib study The European bronchiectasis research group EMBARC will collaborate with Insmed on a 3,000-patient study of brensocatib (Brinsupri) across six countries. The study aims to show whether early treatment can change the disease course, which could expand use and strengthen the case for the drug beyond current approvals.
It signals strong clinical interest and potential for broader use, supporting long-term demand for the main growth driver.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

Q3 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

August 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

Latest21 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.